The propensity score weightings were based on age, prior MDS versus CMML, number of prior therapies for antecedent hematologic disorder, karyotype, prior allogeneic HSCT, and presence of ASXL1, RUNX1 or TP53 mutations. This evidence concerns the gene TP53 and chronic myelomonocytic leukemia.